Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
PaperCitations, authors & open-access status
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,054 citations, 2011 year and closed oa status.
1,054
Citations
2011
Year
closed
OA Status